E2F2/PI3K/AKT signaling pathway

Overview

The E2F2/PI3K/AKT axis connects growth factor signaling to the decision to divide. Ligand binding at receptors such as the epidermal growth factor receptor (EGFR) or the insulin receptor recruits Phosphatidylinositol 3-kinase (PI3K), which phosphorylates membrane PIP2 to PIP3, creating docking sites that bring AKT to the plasma membrane where PDK1 and mTORC2 phosphorylate it. The relationship between AKT and mTOR runs in both directions and is easy to state wrongly: mTORC1/2 complex 2 lies upstream, phosphorylating AKT at Ser473 to complete its activation, while AKT lies upstream of complex 1, relieving its inhibition by phosphorylating TSC2 and PRAS40. Active AKT also phosphorylates FOXO transcription factors to exclude them from the nucleus, and inactivates pro-apoptotic effectors, so the same signal simultaneously drives protein synthesis, alters glucose and lipid metabolism, and suppresses apoptosis.

E2F2 is where this converges on the cell cycle. Growth signaling raises cyclin D, whose CDK4/6 complexes phosphorylate retinoblastoma protein and release the E2F family — E2F2 among the activating members — to transcribe the genes required for S phase. The pathway therefore does not merely favor survival; it removes the restriction point that would otherwise hold a cell out of the cycle in the absence of external signals.

Dysregulation runs in both directions. Constitutive activation, most often through PIK3CA mutation or PTEN loss, supports proliferation and survival in cancer, and the resulting dependence on cyclin D–CDK4/6 is what CDK4/6 inhibitors exploit downstream. Deficient signaling contributes instead to metabolic disease — insulin resistance and the cognitive decline associated with type 2 diabetes — and in hepatocellular disease, hepatitis C virus-mediated suppression of the axis through microRNA regulation produces glycolipid metabolic disorder. Because the pathway integrates growth factors, hormones and nutrient availability, therapeutic strategies pull in opposite directions by context: inhibition in oncology, restoration in metabolic disease.

Recent Publications Summary

Recent publications have examined E2F2/PI3K/AKT signaling in the context of infection-related metabolic dysregulation, cancer, and tissue repair. In hepatitis C virus–associated liver glycolipid metabolism disorders, one study reported that HCV inhibits the E2F2/PI3K/AKT signaling pathway through miR-378b, linking this axis to disturbed hepatic glucose and lipid metabolism 42283974Jun. In a separate cancer-focused study, a natural product from Brassica nigra seeds was evaluated for anticancer potential against cervical cancer, with in silico target screening and network analyses including E2F2-related pathway assessment as part of the mechanistic exploration of γ-sitosterol 42371974Jun.

Several studies in the recent literature positioned PI3K/AKT signaling as a central downstream pathway in natural-product and herbal interventions, although not all specifically focused on E2F2. Verbascoside was investigated in endometrial cancer as a modulator of the LRIG2-PI3K/AKT/mTOR axis to induce apoptosis 42373282Jun, while Loureirin A was reported to exert anti-tumor effects in colorectal cancer cells through inhibition of AKT phosphorylation 42373290Jun. Robinin attenuated DMH-induced colon cancer in rats by modulating Ras/PI3K/Akt/mTOR and NF-κB/Bax/Caspase-3 signaling 42365609Jun, and calcitriol and candesartan were shown to mitigate MSG-exacerbated metabolic syndrome and MASLD/MASH in rats in part by improving hepatic insulin signaling biomarkers including Akt 42362764Jun.

Other publications linked PI3K/AKT signaling to neuroprotection, metastasis, and regenerative responses. Nuciferine improved cognitive impairment and insulin resistance in T2DM by activating PI3K/AKT signaling via the insulin receptor, reversing PI3K and AKT phosphorylation and reducing GSK3β activity. EGCG attenuated arecoline-induced migration and invasion in esophageal squamous cell carcinoma cells in association with EGFR/AKT/P38 signaling 42373249Jun. In bone regeneration, astragaloside IV delivered via a vascular-targeted DNA tetrahedron nanoplatform enhanced distraction osteogenesis through PI3K/AKT/FOXO signaling, activating PI3K/AKT and relieving FOXO1-mediated repression of angiogenic genes 41713052Feb.

What Changes, What Holds

1. HCV-linked metabolic disruption is reinforced, while the E2F2 link remains a mechanistic refinement
REINFORCES The new work stays within the baseline account that hepatitis C virus can suppress this axis and disturb hepatic glycolipid metabolism; it does not overturn the established role of PI3K/AKT in metabolic homeostasis. What it adds is a more specific upstream mediator, miR-378b, and a tighter connection to E2F2-related signaling in the infection setting 42283974Jun. That makes the pathway’s infection biology more concrete, but not conceptually new.

2. PI3K/AKT remains a broadly reused anticancer and metabolic target rather than a new E2F2-specific role
REINFORCES These studies extend the baseline’s view of PI3K/AKT as a central hub in cancer and metabolic disease by showing it is repeatedly engaged by diverse interventions. They do not establish a new function for E2F2/PI3K/AKT, nor do they displace the established model of pathway-driven survival, apoptosis control, and insulin-linked signaling. The main implication is practical: the axis continues to look druggable across tumor and metabolic contexts 42373282Jun42362764Jun.

3. PI3K/AKT signaling is further supported as a shared node in neuroprotection, metastasis control, and tissue repair
REINFORCES Nuciferine’s effects in insulin resistance and cognition fit the baseline’s metabolic and cognitive framing, while the cancer and bone-regeneration findings broaden the range of contexts in which PI3K/AKT is manipulated without contradicting the settled account. The E2F2 component is not central here, so these papers mainly reinforce the pathway’s versatility rather than alter its definition. They suggest the axis remains a common downstream effector across disease and repair states41713052Feb.

Overview update candidates: miR-378b as a more specific mediator of HCV-associated suppression of E2F2/PI3K/AKT signaling; broader confirmation that PI3K/AKT is repeatedly targeted across cancer; metabolic disease; neuroprotection; and tissue repair.